The company will demonstrate how manufacturers can optimize their production processes through seamless integration of design ...
Alys Pharmaceuticals, Inc. ("Alys"), an immune-dermatology focused company, today announces that the first subject has been dosed in a Phase 1/1b study of ALY-301, a first-in-class mast cell selective ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback